JP Morgan Chase
SLN

JP Morgan Chase’s Silence Therapeutics SLN Stock Holding History

JP Morgan Chase’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.7K Sell
3,863
-3,773
-49% -$26.5K ﹤0.01% 6496
2026
Q1 		$38K Sell
7,636
-306
-4% -$1.69K ﹤0.01% 6305
2025
Q4 		$48.3K Buy
7,942
+176
+2% +$1.13K ﹤0.01% 6243
2025
Q3 		$40.3K Buy
7,766
+483
+7% +$2.68K ﹤0.01% 6302
2025
Q2 		$42.2K Sell
7,283
-28,131
-79% -$121K ﹤0.01% 5983
2025
Q1 		$99.9K Buy
35,414
+31,621
+834% +$154K ﹤0.01% 5572
2024
Q4 		$26.1K Buy
+3,793
New +$48.9K ﹤0.01% 6192
2024
Q2 		– Sell
-9,610
Closed -$208K – 7714
2024
Q1 		$208K Buy
+9,610
New +$209K ﹤0.01% 5331
2022
Q1 		– Sell
-6,730
Closed -$157K – 6971
2021
Q4 		$157K Buy
+6,730
New +$156K ﹤0.01% 5482

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

JP Morgan Chase's SLN Position: Q2 2026 in Review

JP Morgan Chase reduced its Silence Therapeutics (SLN) stake by 49% in Q2 2026, selling an estimated $26.5K and leaving 3,863 shares worth $41.7K. The position accounts for ﹤0.01% of the portfolio, ranked #6496.

JP Morgan Chase first reported a position in SLN in Q4 2021 and has held it in 9 quarters since. The position peaked at $208K in Q1 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • JP Morgan Chase held 3,863 shares of Silence Therapeutics worth $41.7K as of Q2 2026.
  • JP Morgan Chase sold 3,773 Silence Therapeutics shares in Q2 2026, an estimated $26.5K.
  • Silence Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6496 holding.
  • JP Morgan Chase first reported a position in Silence Therapeutics in Q4 2021 and has held it in 9 quarters since.
  • JP Morgan Chase's Silence Therapeutics position peaked at $208K in Q1 2024.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.